Supply of medicinal products for chemotherapy and clinical oncology programmes

Summary

The procurement concerns the supply of medicinal products for chemotherapy and clinical oncology programmes for a period of 12 months. It is divided into three lots: dexamethasone phosphate 4 mg/ml in ampoules, amivantamab, and lazertinib tablets. Bidders may submit tenders for all lots. The medicines must be included on the reimbursed-medicines list at the time of tender submission, and their price may not exceed the applicable reimbursement limit. The bidder must hold the required wholesale or manufacturing authorisation for medicinal products. Price is the only award criterion.